title: GlaxoSmithKline's experience of incurred sample reanalysis for dried blood spot samples.
abstract: Dried blood spots are becoming a popular alternative to plasma for many different applications. This has been driven by animal ethics but also by ease of use and cost savings. Recent regulatory guidance now has a requirement for incurred sample reanalysis. This article details three examples of incurred sample reanalysis using dried blood spot samples.
authors.affiliation: Platform Technology & Science, Drug Metabolism & Pharmacokinetics, Worldwide Bioanalysis & Systems Management, GlaxoSmithKline Pharmaceuticals, Park Road, Ware, Hertfordshire, UK. matthew.barfield@gsk.com
authors.forename: Matthew
authors.initials: M
authors.lastname: Barfield
authors.forename: Sheelan
authors.initials: S
authors.lastname: Ahmad
authors.forename: Maria
authors.initials: M
authors.lastname: Busz
mesh_terms: D016477:Artifacts; D001774:Blood Chemical Analysis / Q000379:methods*; D001800:Blood Specimen Collection / Q000379:methods*; D002853:Chromatography, Liquid; D017408:Guidelines as Topic; D006801:Humans; D013058:Mass Spectrometry; D011786:Quality Control; D011934:Reagent Strips / Q000032:analysis*; D015203:Reproducibility of Results; D054928:Validation Studies as Topic
chemical_list: D011934:Reagent Strips